Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 2
2003 5
2004 3
2005 2
2006 1
2009 2
2010 5
2011 11
2012 10
2013 4
2014 6
2015 2
2016 3
2017 10
2018 12
2019 11
2020 9
2021 4
Text availability
Article attribute
Article type
Publication date

Search Results

89 results
Results by year
Filters applied: . Clear all
Page 1
Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial.
Cherney DZI, Dekkers CCJ, Barbour SJ, Cattran D, Abdul Gafor AH, Greasley PJ, Laverman GD, Lim SK, Di Tanna GL, Reich HN, Vervloet MG, Wong MG, Gansevoort RT, Heerspink HJL; DIAMOND investigators. Cherney DZI, et al. Among authors: laverman gd. Lancet Diabetes Endocrinol. 2020 Jul;8(7):582-593. doi: 10.1016/S2213-8587(20)30162-5. Lancet Diabetes Endocrinol. 2020. PMID: 32559474 Clinical Trial.
Effects of Dapagliflozin on Circulating Markers of Phosphate Homeostasis.
de Jong MA, Petrykiv SI, Laverman GD, van Herwaarden AE, de Zeeuw D, Bakker SJL, Heerspink HJL, de Borst MH. de Jong MA, et al. Among authors: laverman gd. Clin J Am Soc Nephrol. 2019 Jan 7;14(1):66-73. doi: 10.2215/CJN.04530418. Epub 2018 Dec 17. Clin J Am Soc Nephrol. 2019. PMID: 30559106 Free PMC article. Clinical Trial.
A Self-management Approach for Dietary Sodium Restriction in Patients With CKD: A Randomized Controlled Trial.
Humalda JK, Klaassen G, de Vries H, Meuleman Y, Verschuur LC, Straathof EJM, Laverman GD, Bos WJW, van der Boog PJM, Vermeulen KM, Blanson Henkemans OA, Otten W, de Borst MH, van Dijk S, Navis GJ; SUBLIME Investigators. Humalda JK, et al. Among authors: laverman gd. Am J Kidney Dis. 2020 Jun;75(6):847-856. doi: 10.1053/j.ajkd.2019.10.012. Epub 2020 Jan 16. Am J Kidney Dis. 2020. PMID: 31955921 Clinical Trial.
Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial.
Tofte N, Lindhardt M, Adamova K, Bakker SJL, Beige J, Beulens JWJ, Birkenfeld AL, Currie G, Delles C, Dimos I, Francová L, Frimodt-Møller M, Girman P, Göke R, Havrdova T, Heerspink HJL, Kooy A, Laverman GD, Mischak H, Navis G, Nijpels G, Noutsou M, Ortiz A, Parvanova A, Persson F, Petrie JR, Ruggenenti PL, Rutters F, Rychlík I, Siwy J, Spasovski G, Speeckaert M, Trillini M, Zürbig P, von der Leyen H, Rossing P; PRIORITY investigators. Tofte N, et al. Among authors: laverman gd. Lancet Diabetes Endocrinol. 2020 Apr;8(4):301-312. doi: 10.1016/S2213-8587(20)30026-7. Epub 2020 Mar 2. Lancet Diabetes Endocrinol. 2020. PMID: 32135136 Clinical Trial.
89 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page